title: Azilsartan: Novel Angiotensin Receptor Blocker.
abstract: To describe the efficacy and safety profile of the new angiotensin receptor blocker (ARB), "Azilsartan Medoxomil", reviewing data available from both clinical and pre-clinical studies.
  
  
  
  We completed a review of the English literature from PubMed using the keywords- azilsartan medoxomil, angiotensin receptor blockers (ARB), angiotensin converting enzyme inhibitors (ACEi) and hypertension.
  
  
  
  Many clinical trials have been conducted comparing the efficacy of azilsartan with other ARB's and also with the ACEi ramipril. The trials have shown azilsartan to be more effective in reducing the mean 24-hour systolic blood pressure compared to its counterparts.
  
  
  
  Azilsartan is a recently approved ARB and appears to be more efficacious in reducing blood pressure (BP) than the other ARBs with a similar safety and tolerability profile. Azilsartan's very high affinity to and slow dissociation from the angiotensin 1 receptor (AT1R) along with its inverse agonistic properties make it a very good candidate for clinical effects beyond simple BP control, potentially counteracting cardiac hypertrophy, cardiac fibrosis and insulin resistance, together with improved reno-protection and atherosclerotic plaque stabilization.
authors.affiliation: Consulting Physician and Cardiologist, Lilavati, Seven Hills and L.H. Hiranandani Hospital.
authors.forename: Ramesh R
authors.initials: RR
authors.lastname: Dargad
authors.affiliation: Medical Graduate, B.J. Medical College, Pune, Maharashtra.
authors.forename: Jai D
authors.initials: JD
authors.lastname: Parekh
authors.affiliation: Senior Registrar, ICU-Fortis Hospital, Mumbai, Maharashtra.
authors.forename: Rohit R
authors.initials: RR
authors.lastname: Dargad
authors.affiliation: Internal Medicine Resident, Creighton University, Nebraska, USA.
authors.forename: Shweta
authors.initials: S
authors.lastname: Kukrety
mesh_terms: D047228:Angiotensin II Type 1 Receptor Blockers / Q000009:adverse effects / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001562:Benzimidazoles / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D002752:Chlorthalidone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D004347:Drug Interactions; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D010069:Oxadiazoles / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000959:Antihypertensive Agents; D001562:Benzimidazoles; D004338:Drug Combinations; D010069:Oxadiazoles; C557413:azilsartan medoxomil; D002752:Chlorthalidone